José A. Hidalgo

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

Michael Aboud, Richard Kaplan, Johannes Lombaard et al. · The Lancet Infectious Diseases · 2019 · 198 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Risk of cancers during interrupted antiretroviral therapy in the SMART study

Michael J. Silverberg, Jacqueline Neuhaus, Mark Bower et al. · AIDS · 2007 · 136 citations

Public Health, Oncology, Pharmacotherapy +14

Submandibular gland needle biopsy for the diagnosis of Parkinson disease

Charles H. Adler, Brittany N. Dugger, Michael L. Hinni et al. · Neurology · 2014 · 132 citations · Full text

Medicine, Neurology, Pathology +14

Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease

Thomas G. Beach, Charles H. Adler, Brittany N. Dugger et al. · Journal of Neuropathology & Experimental Neurology · 2013 · 115 citations · Full text

Life Sciences, Neurology, Pathology +15